Could licorice root make CAR-T cancer therapy safer and stronger?
NCT ID NCT07616271
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a compound from licorice root, called diammonium glycyrrhizinate, can reduce the toxic side effects and improve the cancer-killing power of CAR-T cell therapy in people with large B-cell lymphoma. About 21 participants will receive either standard care or the licorice extract alongside their CAR-T treatment, and researchers will track side effects and remission rates. The goal is to make this advanced therapy both safer and more effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
diammonium glycyrrhizinate (a compound from licorice root)
What this could lead to
If it works, this could make CAR-T cell therapy safer and more effective for people with large B-cell lymphoma.
What could go wrong
This is a small, early-stage trial with only 21 participants, so results may not apply to everyone. The treatment requires taking the drug for 2 years, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••